{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:51Z","timestamp":1790769351166,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":98,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_5","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:34:26Z","timestamp":1790764466000},"page":"83-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy"],"prefix":"10.1007","author":[{"given":"Tejal","family":"Aslesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"175628641877693","DOI":"10.1177\/1756286418776932","volume":"11","author":"CD Wurster","year":"2018","unstructured":"Wurster CD, Ludolph AC (2018) Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord 11:1756286418776932. https:\/\/doi.org\/10.1177\/1756286418776932","journal-title":"Ther Adv Neurol Disord"},{"key":"5_CR2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","volume":"94","author":"KM Schoch","year":"2017","unstructured":"Schoch KM, Miller TM (2017) Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron 94:1056\u20131070. https:\/\/doi.org\/10.1016\/j.neuron.2017.04.010","journal-title":"Neuron"},{"key":"5_CR3","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano RL (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44:6518\u20136548. https:\/\/doi.org\/10.1093\/nar\/gkw236","journal-title":"Nucleic Acids Res"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259\u2013293. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105654","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.01.008","journal-title":"Adv Drug Deliv Rev"},{"key":"5_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Baker BF, Crooke RM, Liang X-H (2021) Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20:427\u2013453. https:\/\/doi.org\/10.1038\/s41573-021-00162-z","journal-title":"Nat Rev Drug Discov"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN et al. (2014) Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35:2146\u20132157. https:\/\/doi.org\/10.1093\/eurheartj\/ehu274","journal-title":"Eur Heart J"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:998\u20131006. https:\/\/doi.org\/10.1016\/S0140-6736(10)60284-X","journal-title":"Lancet"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jacl.2018.03.031","volume":"12","author":"M Davidson","year":"2018","unstructured":"Davidson M, Stevenson M, Hsieh A et al. (2018) Examing the high disease burden and impact on quality of life in familial chylomicronemia syndrome. J Clin Lipidol 12:536\u2013537. https:\/\/doi.org\/10.1016\/j.jacl.2018.03.031","journal-title":"J Clin Lipidol"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-4684-5296-9_9","volume-title":"Cardiovascular disease: molecular and cellular mechanisms, prevention, and treatment","author":"RW Mahley","year":"1987","unstructured":"Mahley RW (1987) Receptor-mediated regulation of cholesterol metabolism. In: Gallo LL (Ed.)Eds. Cardiovascular disease: molecular and cellular mechanisms, prevention, and treatment. Springer US, Boston, MA, 79\u201385pp"},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"CA Stein","year":"2017","unstructured":"Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther 25:1069\u20131075. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.023","journal-title":"Mol Ther"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2165\/11635060-000000000-00000","volume":"72","author":"C Gelsinger","year":"2012","unstructured":"Gelsinger C, Steinhagen-Thiessen E, Kassner U (2012) Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs 72:1445\u20131455. https:\/\/doi.org\/10.2165\/11635060-000000000-00000","journal-title":"Drugs"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"a2423","DOI":"10.1136\/bmj.a2423","volume":"337","author":"J Versmissen","year":"2008","unstructured":"Versmissen J, Oosterveer DM, Yazdanpanah M et al. (2008) Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337:a2423. https:\/\/doi.org\/10.1136\/bmj.a2423","journal-title":"BMJ"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.amjcard.2011.03.027","volume":"108","author":"A Elis","year":"2011","unstructured":"Elis A, Zhou R, Stein EA (2011) Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol 108:223\u2013226. https:\/\/doi.org\/10.1016\/j.amjcard.2011.03.027","journal-title":"Am J Cardiol"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJP et al. (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437\u20132445. https:\/\/doi.org\/10.1001\/jama.294.19.2437","journal-title":"JAMA"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.amjcard.2010.03.033","volume":"106","author":"TR Pedersen","year":"2010","unstructured":"Pedersen TR, Cater NB, Faergeman O et al. (2010) Comparison of Atorvastatin 80 mg\/day versus Simvastatin 20 to 40 mg\/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the incremental decrease in end points through aggressive lipid lowering [IDEAL] trial). Am J Cardiol 106:354\u2013359. https:\/\/doi.org\/10.1016\/j.amjcard.2010.03.033","journal-title":"Am J Cardiol"},{"key":"5_CR17","doi-asserted-by":"publisher","unstructured":"Cholesterol Treatment Trialists' (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90\u2008056 participants in 14 randomised trials of statins. Lancet 366:1267\u20131278. https:\/\/doi.org\/10.1016\/S0140-6736(05)67394-1","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"European Association for Cardiovasc","year":"2011","unstructured":"European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL et al. (2011) ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769\u20131818. https:\/\/doi.org\/10.1093\/eurheartj\/ehr158","journal-title":"Eur Heart J"},{"key":"5_CR19","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.2174\/13816128113199990312","volume":"19","author":"C Gebhard","year":"2013","unstructured":"Gebhard C, Huard G, Kritikou EA, Tardif J-C (2013) Apolipoprotein B antisense inhibition \u2013 update on mipomersen. Curr Pharm Des 19:3132\u20133142. https:\/\/doi.org\/10.2174\/13816128113199990312","journal-title":"Curr Pharm Des"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1124\/dmd.106.012401","volume":"35","author":"RZ Yu","year":"2007","unstructured":"Yu RZ, Kim T-W, Hong A et al. (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35:460\u2013468. https:\/\/doi.org\/10.1124\/dmd.106.012401","journal-title":"Drug Metab Dispos"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","volume":"77","author":"RZ Yu","year":"2009","unstructured":"Yu RZ, Lemonidis KM, Graham MJ et al. (2009) Cross-species comparison of in vivo PK\/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 77:910\u2013919. https:\/\/doi.org\/10.1016\/j.bcp.2008.11.005","journal-title":"Biochem Pharmacol"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","volume":"20","author":"JS Parham","year":"2019","unstructured":"Parham JS (2019) Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmacother 20:127\u2013131. https:\/\/doi.org\/10.1080\/14656566.2018.1550071","journal-title":"Expert Opin Pharmacother"},{"key":"5_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","volume":"46","author":"RM Crooke","year":"2005","unstructured":"Crooke RM, Graham MJ, Lemonidis KM et al. (2005) An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 46:872\u2013884. https:\/\/doi.org\/10.1194\/jlr.M400492-JLR200","journal-title":"J Lipid Res"},{"key":"5_CR24","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","volume":"114","author":"JJP Kastelein","year":"2006","unstructured":"Kastelein JJP, Wedel MK, Baker BF et al. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114:1729\u20131735. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.606442","journal-title":"Circulation"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1093\/eurheartj\/ehr148","volume":"32","author":"F Akdim","year":"2011","unstructured":"Akdim F, Tribble DL, Flaim JD et al. (2011) Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 32:2650\u20132659. https:\/\/doi.org\/10.1093\/eurheartj\/ehr148","journal-title":"Eur Heart J"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","volume":"73","author":"P Hair","year":"2013","unstructured":"Hair P, Cameron F, McKeage K (2013) Mipomersen sodium: first global approval. Drugs 73:487\u2013493. https:\/\/doi.org\/10.1007\/s40265-013-0042-2","journal-title":"Drugs"},{"key":"5_CR27","unstructured":"Genzyme and Isis Announce FDA approval of KYNAMROTM (mipomersen sodium) injection for the treatment of homozygous familial hypercholesterolemia, Ionis Pharmaceuticals, Inc. https:\/\/ir.ionis.com\/news-releases\/news-release-details\/genzyme-and-isis-announce-fda-approval-kynamrotm-mipomersen. Accessed 24 Oct 2025"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK et al. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37:161\u2013165. https:\/\/doi.org\/10.1038\/ng1509","journal-title":"Nat Genet"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH (2006) Sequence variations in PCSK9, Low LDL, and protection against coronary heart disease. N Engl J Med 354:1264\u20131272. https:\/\/doi.org\/10.1056\/NEJMoa054013","journal-title":"N Engl J Med"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.5551\/jat.RV17065","volume":"29","author":"A Bajaj","year":"2022","unstructured":"Bajaj A, Cuchel M (2022) Advancements in the treatment of homozygous familial hypercholesterolemia. J Atheroscler Thromb 29:1125\u20131135. https:\/\/doi.org\/10.5551\/jat.RV17065","journal-title":"J Atheroscler Thromb"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/ph16010064","volume":"16","author":"M Kayikcioglu","year":"2023","unstructured":"Kayikcioglu M, Tokgozoglu L (2023) Current treatment options in homozygous familial hypercholesterolemia. Pharmaceuticals 16:64. https:\/\/doi.org\/10.3390\/ph16010064","journal-title":"Pharmaceuticals"},{"key":"5_CR32","unstructured":"Center for Drug Evaluation and Research (2021) FDA approves add-on therapy to lower cholesterol among certain high-risk adults. FDA"},{"key":"5_CR33","unstructured":"US FDA approves expanded indication for Novartis Leqvio\u00ae (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease. In: Novartis, U.S. Am. https:\/\/www.novartis.com\/us-en\/news\/media-releases\/us-fda-approves-expanded-indication-novartis-leqvio-inclisiran-include-treatment-adults-high-ldl-c-and-who-are-increased-risk-heart-disease. Accessed 24 Oct 2025"},{"key":"5_CR34","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/nu5030981","volume":"5","author":"A Brahm","year":"2013","unstructured":"Brahm A, Hegele RA (2013) Hypertriglyceridemia. Nutrients 5:981\u20131001. https:\/\/doi.org\/10.3390\/nu5030981","journal-title":"Nutrients"},{"key":"5_CR35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ et al. (2014) The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2:655\u2013666. https:\/\/doi.org\/10.1016\/S2213-8587(13)70191-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1210\/er.2014-1062","volume":"36","author":"GF Lewis","year":"2015","unstructured":"Lewis GF, Xiao C, Hegele RA (2015) Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev 36:131\u2013147. https:\/\/doi.org\/10.1210\/er.2014-1062","journal-title":"Endocr Rev"},{"key":"5_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1194\/jlr.R009720","volume":"52","author":"CT Johansen","year":"2011","unstructured":"Johansen CT, Kathiresan S, Hegele RA (2011) Genetic determinants of plasma triglycerides. J Lipid Res 52:189\u2013206. https:\/\/doi.org\/10.1194\/jlr.R009720","journal-title":"J Lipid Res"},{"key":"5_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.bbalip.2011.10.007","volume":"1821","author":"CT Johansen","year":"2012","unstructured":"Johansen CT, Hegele RA (2012) Allelic and phenotypic spectrum of plasma triglycerides. Biochim Biophys Acta BBA Mol Cell Biol Lipids 1821:833\u2013842. https:\/\/doi.org\/10.1016\/j.bbalip.2011.10.007","journal-title":"Biochim Biophys Acta BBA Mol Cell Biol Lipids"},{"key":"5_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/MOL.0b013e3283471972","volume":"22","author":"CT Johansen","year":"2011","unstructured":"Johansen CT, Hegele RA (2011) Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol 22:247. https:\/\/doi.org\/10.1097\/MOL.0b013e3283471972","journal-title":"Curr Opin Lipidol"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1742-1241.2007.01678.x","volume":"62","author":"DC Chan","year":"2008","unstructured":"Chan DC, Chen MM, Ooi EMM, Watts GF (2008) An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?. Int J Clin Pract 62:799\u2013809. https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01678.x","journal-title":"Int J Clin Pract"},{"key":"5_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2017.05.003","volume":"30","author":"I Gouni-Berthold","year":"2017","unstructured":"Gouni-Berthold I (2017) The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia. Atheroscler Suppl 30:19\u201327. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.003","journal-title":"Atheroscler Suppl"},{"key":"5_CR42","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF et al. (2015) Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 373:438\u2013447. https:\/\/doi.org\/10.1056\/NEJMoa1400283","journal-title":"N Engl J Med"},{"key":"5_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/ATVBAHA.109.197830","volume":"30","author":"CO Mendivil","year":"2010","unstructured":"Mendivil CO, Zheng C, Furtado J et al. (2010) Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol 30:239\u2013245. https:\/\/doi.org\/10.1161\/ATVBAHA.109.197830","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1126\/science.1161524","volume":"322","author":"TI Pollin","year":"2008","unstructured":"Pollin TI, Damcott CM, Shen H et al. (2008) A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322:1702\u20131705. https:\/\/doi.org\/10.1126\/science.1161524","journal-title":"Science"},{"key":"5_CR45","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru K, Pirruccello JP, Do R et al. (2010) Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 363:2220\u20132227. https:\/\/doi.org\/10.1056\/NEJMoa1002926","journal-title":"N Engl J Med"},{"key":"5_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. (2014) Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease. N Engl J Med 371:32\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1308027","journal-title":"N Engl J Med"},{"key":"5_CR47","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.2337\/diacare.27.6.1358","volume":"27","author":"GM Dallinga-Thie","year":"2004","unstructured":"Dallinga-Thie GM, Berk-Planken IIL, Bootsma AH et al. (2004) Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care 27:1358\u20131364. https:\/\/doi.org\/10.2337\/diacare.27.6.1358","journal-title":"Diabetes Care"},{"key":"5_CR48","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.2337\/dc08-0358","volume":"31","author":"EMM Ooi","year":"2008","unstructured":"Ooi EMM, Watts GF, Chan DC et al. (2008) Dose-dependent effect of rosuvastatin on VLDL\u2013apolipoprotein C-III kinetics in the metabolic syndrome. Diabetes Care 31:1656\u20131661. https:\/\/doi.org\/10.2337\/dc08-0358","journal-title":"Diabetes Care"},{"key":"5_CR49","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00044011-199815060-00003","volume":"15","author":"E Swahn","year":"1998","unstructured":"Swahn E, von Schenck H, Olsson AG (1998) Omega- 3 ethyl ester concentrate decreases total apolipoprotein ciii and increases antithrombin III in postmyocardial infarction patients. Clin Drug Investig 15:473\u2013482. https:\/\/doi.org\/10.2165\/00044011-199815060-00003","journal-title":"Clin Drug Investig"},{"key":"5_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/13543784.2019.1582028","volume":"28","author":"D Milonas","year":"2019","unstructured":"Milonas D, Tziomalos K (2019) Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia \u2013 spotlight on volanesorsen. Expert Opin Investig Drugs 28:389\u2013394. https:\/\/doi.org\/10.1080\/13543784.2019.1582028","journal-title":"Expert Opin Investig Drugs"},{"key":"5_CR51","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell TA et al. (2013) Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 112:1479\u20131490. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.300367","journal-title":"Circ Res"},{"key":"5_CR52","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1210\/jc.2011-3213","volume":"97","author":"L Berglund","year":"2012","unstructured":"Berglund L, Brunzell JD, Goldberg AC et al. (2012) Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 97:2969\u20132989. https:\/\/doi.org\/10.1210\/jc.2011-3213","journal-title":"J Clin Endocrinol Metab"},{"key":"5_CR53","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc16-0126","volume":"39","author":"A Digenio","year":"2016","unstructured":"Digenio A, Dunbar RL, Alexander VJ et al. (2016) Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care 39:1408\u20131415. https:\/\/doi.org\/10.2337\/dc16-0126","journal-title":"Diabetes Care"},{"key":"5_CR54","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.metabol.2014.08.010","volume":"63","author":"L Wu","year":"2014","unstructured":"Wu L, Parhofer KG (2014) Diabetic dyslipidemia. Metabolism 63:1469\u20131479. https:\/\/doi.org\/10.1016\/j.metabol.2014.08.010","journal-title":"Metabolism"},{"key":"5_CR55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1161\/01.ATV.0000046230.02211.B4","volume":"23","author":"WH Capell","year":"2003","unstructured":"Capell WH, DeSouza CA, Poirier P et al. (2003) Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 23:307\u2013313. https:\/\/doi.org\/10.1161\/01.ATV.0000046230.02211.B4","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5_CR56","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K et al. (2014) Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371:2200\u20132206. https:\/\/doi.org\/10.1056\/NEJMoa1400284","journal-title":"N Engl J Med"},{"key":"5_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ahj.2025.03.003","volume":"286","author":"NA Marston","year":"2025","unstructured":"Marston NA, Bergmark BA, Alexander VJ et al. (2025) Design and rationale of the CORE-TIMI\u202f72a and CORE2-TIMI\u202f72b trials of olezarsen in patients with severe hypertriglyceridemia. Am Heart J 286:125\u2013135. https:\/\/doi.org\/10.1016\/j.ahj.2025.03.003","journal-title":"Am Heart J"},{"key":"5_CR58","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA et al. (2024) Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med 390:1770\u20131780. https:\/\/doi.org\/10.1056\/NEJMoa2402309","journal-title":"N Engl J Med"},{"key":"5_CR59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","volume":"52","author":"A Tikka","year":"2016","unstructured":"Tikka A, Jauhiainen M (2016) The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine 52:187\u2013193. https:\/\/doi.org\/10.1007\/s12020-015-0838-9","journal-title":"Endocrine"},{"key":"5_CR60","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/ATVBAHA.122.317966","volume":"43","author":"HN Ginsberg","year":"2023","unstructured":"Ginsberg HN, Goldberg IJ (2023) Broadening the scope of dyslipidemia therapy by targeting apoc3 (apolipoprotein C3) and ANGPTL3 (angiopoietin-like protein 3. Arterioscler Thromb Vasc Biol 43:388\u2013398. https:\/\/doi.org\/10.1161\/ATVBAHA.122.317966","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5_CR61","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham MJ, Lee RG, Brandt TA et al. (2017) Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med 377:222\u2013232. https:\/\/doi.org\/10.1056\/NEJMoa1701329","journal-title":"N Engl J Med"},{"key":"5_CR62","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2018.2866","volume":"3","author":"LA Lotta","year":"2018","unstructured":"Lotta LA, Stewart ID, Sharp SJ et al. (2018) Association of genetically enhanced lipoprotein lipase\u2013mediated lipolysis and low-density lipoprotein cholesterol\u2013lowering alleles with risk of coronary disease and type 2 diabetes. JAMA Cardiol 3:957\u2013966. https:\/\/doi.org\/10.1001\/jamacardio.2018.2866","journal-title":"JAMA Cardiol"},{"key":"5_CR63","unstructured":"Pfizer and Ionis announce discontinuation of vupanorsen clinical development program. Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-ionis-announce-discontinuation-vupanorsen. Accessed 24 Oct 2025"},{"key":"5_CR64","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tcm.2019.03.001","volume":"30","author":"V Chyzhyk","year":"2020","unstructured":"Chyzhyk V, Brown AS (2020) Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med 30:80\u201385. https:\/\/doi.org\/10.1016\/j.tcm.2019.03.001","journal-title":"Trends Cardiovasc Med"},{"key":"5_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","volume":"23","author":"E Stroes","year":"2017","unstructured":"Stroes E, Moulin P, Parhofer KG et al. (2017) Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl 23:1\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2016.10.002","journal-title":"Atheroscler Suppl"},{"key":"5_CR66","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1124\/jpet.115.229740","volume":"356","author":"T Sakurai","year":"2016","unstructured":"Sakurai T, Sakurai A, Vaisman BL et al. (2016) Creation of apolipoprotein C-II (ApoC-II) mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptide. J Pharmacol Exp Ther 356:341\u2013353. https:\/\/doi.org\/10.1124\/jpet.115.229740","journal-title":"J Pharmacol Exp Ther"},{"key":"5_CR67","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2015.26","volume":"11","author":"AJ Brahm","year":"2015","unstructured":"Brahm AJ, Hegele RA (2015) Chylomicronaemia\u2014current diagnosis and future therapies. Nat Rev Endocrinol 11:352\u2013362. https:\/\/doi.org\/10.1038\/nrendo.2015.26","journal-title":"Nat Rev Endocrinol"},{"key":"5_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5551\/jat.10702","volume":"19","author":"T Gotoda","year":"2012","unstructured":"Gotoda T, Shirai K, Ohta T et al. (2012) Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb 19:1\u201312. https:\/\/doi.org\/10.5551\/jat.10702","journal-title":"J Atheroscler Thromb"},{"key":"5_CR69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1475-2840-11-125","volume":"11","author":"A Tenenbaum","year":"2012","unstructured":"Tenenbaum A, Fisman EZ (2012) Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 11:125. https:\/\/doi.org\/10.1186\/1475-2840-11-125","journal-title":"Cardiovasc Diabetol"},{"key":"5_CR70","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","volume":"12","author":"DJ Blom","year":"2018","unstructured":"Blom DJ, O\u2019Dea L, Digenio A et al. (2018) Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study. J Clin Lipidol 12:1234\u20131243.e5. https:\/\/doi.org\/10.1016\/j.jacl.2018.05.013","journal-title":"J Clin Lipidol"},{"key":"5_CR71","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/14779072.2018.1487290","volume":"16","author":"M Arca","year":"2018","unstructured":"Arca M, Hsieh A, Soran H et al. (2018) The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Rev Cardiovasc Ther 16:537\u2013546. https:\/\/doi.org\/10.1080\/14779072.2018.1487290","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"5_CR72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosissup.2018.04.042","volume":"32","author":"D Gaudet","year":"2018","unstructured":"Gaudet D, Digenio A, Alexander VJ et al. (2018) The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with FCS. Atheroscler Suppl 32:14\u201315. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2018.04.042","journal-title":"Atheroscler Suppl"},{"key":"5_CR73","unstructured":"Akcea and Ionis announce approval of WAYLIVRA\u00ae (volanesorsen) in the European Union. Ionis Pharmaceuticals, Inc. https:\/\/ir.ionis.com\/news-releases\/news-release-details\/akcea-and-ionis-announce-approval-waylivrar-volanesorsen. Accessed 24 Oct 2025"},{"key":"5_CR74","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","volume":"79","author":"J Paik","year":"2019","unstructured":"Paik J, Duggan S (2019) Volanesorsen: first global approval. Drugs 79:1349\u20131354. https:\/\/doi.org\/10.1007\/s40265-019-01168-z","journal-title":"Drugs"},{"key":"5_CR75","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","volume":"40","author":"VJ Alexander","year":"2019","unstructured":"Alexander VJ, Xia S, Hurh E et al. (2019) N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J 40:2785\u20132796. https:\/\/doi.org\/10.1093\/eurheartj\/ehz209","journal-title":"Eur Heart J"},{"key":"5_CR76","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E et al. (2024) Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med 390:1781\u20131792. https:\/\/doi.org\/10.1056\/NEJMoa2400201","journal-title":"N Engl J Med"},{"key":"5_CR77","doi-asserted-by":"publisher","first-page":"E1676","DOI":"10.1210\/jc.2014-1878","volume":"99","author":"J Joseph","year":"2014","unstructured":"Joseph J, Shamburek RD, Cochran EK et al. (2014) Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. J Clin Endocrinol Metab 99:E1676\u2013E1680. https:\/\/doi.org\/10.1210\/jc.2014-1878","journal-title":"J Clin Endocrinol Metab"},{"key":"5_CR78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","volume":"19","author":"Y Handelsman","year":"2013","unstructured":"Handelsman Y, Oral EA, Bloomgarden ZT et al. (2013) The clinical approach to the detection of lipodystrophy \u2013 an AACE consensus statement. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 19:107\u2013116. https:\/\/doi.org\/10.4158\/endp.19.1.v767575m65p5mr06","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"5_CR79","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4158\/EP09154.RA","volume":"16","author":"JL Chan","year":"2010","unstructured":"Chan JL, Oral EA (2010) Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract 16:310\u2013323. https:\/\/doi.org\/10.4158\/EP09154.RA","journal-title":"Endocr Pract"},{"key":"5_CR80","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1399-0004.2009.01350.x","volume":"78","author":"L Subramanyam","year":"2010","unstructured":"Subramanyam L, Simha V, Garg A (2010) Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A\/C mutations. Clin Genet 78:66\u201373. https:\/\/doi.org\/10.1111\/j.1399-0004.2009.01350.x","journal-title":"Clin Genet"},{"key":"5_CR81","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"Garg A (2004) Acquired and Inherited Lipodystrophies. N Engl J Med 350:1220\u20131234. https:\/\/doi.org\/10.1056\/NEJMra025261","journal-title":"N Engl J Med"},{"key":"5_CR82","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cen.13311","volume":"86","author":"N Ajluni","year":"2017","unstructured":"Ajluni N, Meral R, Neidert AH et al. (2017) Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clin Endocrinol 86:698\u2013707. https:\/\/doi.org\/10.1111\/cen.13311","journal-title":"Clin Endocrinol"},{"key":"5_CR83","unstructured":"Familial Partial Lipodystrophy \u2013 Symptoms, Causes, Treatment. NORD. https:\/\/rarediseases.org\/rare-diseases\/familial-partial-lipodystrophy\/. Accessed 24 Oct 2025"},{"key":"5_CR84","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1210\/jc.2015-3891","volume":"101","author":"A Kassai","year":"2016","unstructured":"Kassai A, Muniyappa R, Levenson AE et al. (2016) Effect of leptin administration on circulating apolipoprotein CIII levels in patients with lipodystrophy. J Clin Endocrinol Metab 101:1790\u20131797. https:\/\/doi.org\/10.1210\/jc.2015-3891","journal-title":"J Clin Endocrinol Metab"},{"key":"5_CR85","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","volume":"16","author":"EA Oral","year":"2022","unstructured":"Oral EA, Garg A, Tami J et al. (2022) Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: volanesorsen in FPLD; the BROADEN study. J Clin Lipidol 16:833\u2013849. https:\/\/doi.org\/10.1016\/j.jacl.2022.08.008","journal-title":"J Clin Lipidol"},{"key":"5_CR86","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ (2018) Inotersen: first global approval. Drugs 78:1371\u20131376. https:\/\/doi.org\/10.1007\/s40265-018-0968-5","journal-title":"Drugs"},{"key":"5_CR87","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti G, Brambilla L, Rossi D (2017) Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci 38:406\u2013424. https:\/\/doi.org\/10.1016\/j.tips.2017.01.003","journal-title":"Trends Pharmacol Sci"},{"key":"5_CR88","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1089\/nat.2016.0652","volume":"27","author":"F Shabanpoor","year":"2017","unstructured":"Shabanpoor F, Hammond SM, Abendroth F et al. (2017) Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy. Nucleic Acid Ther 27:130\u2013143. https:\/\/doi.org\/10.1089\/nat.2016.0652","journal-title":"Nucleic Acid Ther"},{"key":"5_CR89","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al. (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci 114:4213\u20134218. https:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"5_CR90","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.160516","volume":"8","author":"T Aslesh","year":"2023","unstructured":"Aslesh T, Erkut E, Ren J et al. (2023) DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration. JCI Insight 8(5):e160516. https:\/\/doi.org\/10.1172\/jci.insight.160516","journal-title":"JCI Insight"},{"key":"5_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59494-8","volume":"16","author":"MNA Shah","year":"2025","unstructured":"Shah MNA, Wilton-Clark H, Haque F et al. (2025) DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function. Nat Commun 16:4477. https:\/\/doi.org\/10.1038\/s41467-025-59494-8","journal-title":"Nat Commun"},{"key":"5_CR92","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","volume":"17","author":"H Yin","year":"2008","unstructured":"Yin H, Moulton HM, Seow Y et al. (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17:3909\u20133918. https:\/\/doi.org\/10.1093\/hmg\/ddn293","journal-title":"Hum Mol Genet"},{"key":"5_CR93","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1146\/annurev-bioeng-071910-124709","volume":"13","author":"L Huang","year":"2011","unstructured":"Huang L, Liu Y (2011) In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 13:507\u2013530. https:\/\/doi.org\/10.1146\/annurev-bioeng-071910-124709","journal-title":"Annu Rev Biomed Eng"},{"key":"5_CR94","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1021\/mp500259e","volume":"11","author":"A Babu","year":"2014","unstructured":"Babu A, Wang Q, Muralidharan R et al. (2014) Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA\/plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm 11:2720\u20132733. https:\/\/doi.org\/10.1021\/mp500259e","journal-title":"Mol Pharm"},{"key":"5_CR95","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/nass\/nrn280","volume":"52","author":"PP Seth","year":"2008","unstructured":"Seth PP, Siwkowski A, Allerson CR et al. (2008) Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. Nucleic Acids Symp Ser 52:553\u2013554. https:\/\/doi.org\/10.1093\/nass\/nrn280","journal-title":"Nucleic Acids Symp Ser"},{"key":"5_CR96","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","volume":"37","author":"W Shen","year":"2019","unstructured":"Shen W, De Hoyos CL, Migawa MT et al. (2019) Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol 37:640\u2013650. https:\/\/doi.org\/10.1038\/s41587-019-0106-2","journal-title":"Nat Biotechnol"},{"key":"5_CR97","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4062\/biomolther.2023.001","volume":"31","author":"Y Kim","year":"2023","unstructured":"Kim Y (2023) Drug discovery perspectives of antisense oligonucleotides. Biomol Ther 31:241\u2013252. https:\/\/doi.org\/10.4062\/biomolther.2023.001","journal-title":"Biomol Ther"},{"key":"5_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202500584","volume":"26","author":"J Bhamra","year":"2025","unstructured":"Bhamra J, Krishna M, Samman G et al. (2025) Toxicity of antisense oligonucleotides is determined by the synergistic interplay of chemical modifications and nucleotide sequences, not by either factor alone. ChemBioChem 26:e202500584. https:\/\/doi.org\/10.1002\/cbic.202500584","journal-title":"ChemBioChem"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:02:58Z","timestamp":1790766178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":98,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_5","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}